Gabapentin Off-Label Prescribing & Legal Implications

Pfizer's $430 Million Off-Label Promotion Scheme

In 2004, Warner-Lambert (acquired by Pfizer in 2000) pleaded guilty to two federal felony counts of violating the Food, Drug, and Cosmetic Act by promoting gabapentin (marketed as Neurontin) for unapproved uses. The company paid $430 million — $240 million in criminal fines and $190 million to settle civil False Claims Act allegations. Federal prosecutors proved that Warner-Lambert had implemented a systematic campaign to promote Neurontin for at least eleven unapproved conditions, including migraine prevention, bipolar disorder, pain management, attention deficit disorder, restless leg syndrome, drug and alcohol withdrawal, and other conditions for which the drug had no FDA-approved indication.

Internal company documents revealed that Warner-Lambert paid physicians to attach their names to ghostwritten articles promoting off-label uses, funded sham advisory boards and speaker programs to disseminate off-label messaging, planted favorable articles in medical literature through publication planning firms, and trained sales representatives to proactively promote unapproved uses in physician offices. The company's own projections estimated that off-label uses would generate the majority of Neurontin revenue — a prediction that proved accurate as off-label prescribing came to dominate the drug's market. Despite the criminal conviction, Pfizer never undertook the clinical trials necessary to establish safety and efficacy for these off-label uses, including comprehensive cognitive safety testing in the populations now receiving the drug.

The 80 Percent Off-Label Reality

Gabapentin's FDA-approved indications are narrow: postherpetic neuralgia (shingles pain) in adults and adjunctive therapy for partial seizures in patients aged 3 and older. Yet studies consistently show that 83 to 95 percent of gabapentin prescriptions are written for off-label purposes. The most common off-label uses include general neuropathic pain, lower back pain, fibromyalgia, migraine prevention, anxiety disorders, insomnia, alcohol use disorder, and various other chronic pain conditions. For many of these uses, the clinical evidence supporting gabapentin's efficacy is weak or nonexistent — a Cochrane review found that gabapentin is ineffective for low back pain, and trials for fibromyalgia have shown modest benefit at best.

The off-label prescribing explosion was further fueled by the opioid crisis. As regulators, insurers, and medical boards pressured physicians to reduce opioid prescribing beginning around 2016, gabapentin emerged as a convenient alternative — perceived as non-addictive (a claim now disputed), inexpensive as a generic, and broadly tolerated. This massive shift in prescribing patterns occurred without adequate safety surveillance or clinical trials demonstrating gabapentin's cognitive safety profile in the expanded patient populations now receiving the drug. Millions of Americans were prescribed gabapentin for pain conditions where it had no proven efficacy and unknown cognitive risks.

How Off-Label Prescribing Amplifies Cognitive Risk

When a drug is prescribed off-label, the informed consent process is fundamentally compromised. For FDA-approved indications, the prescribing information provides detailed safety data drawn from clinical trials conducted in the relevant patient population. For off-label uses, no such population-specific safety data exists. Patients prescribed gabapentin for chronic back pain, anxiety, or insomnia cannot be properly informed about their cognitive risk because that risk has never been formally studied in their population. They consent to treatment based on incomplete information, a situation created by the manufacturer's decision to market the drug for unapproved uses without pursuing the clinical trials necessary to characterize safety.

Furthermore, off-label uses often involve higher doses and longer treatment durations than FDA-approved indications. Postherpetic neuralgia, the primary approved use, is typically a self-limiting condition lasting months to a few years, whereas off-label uses like chronic back pain or fibromyalgia are lifelong conditions that result in decades of continuous gabapentin exposure. The 2025 JAMA Internal Medicine study found that duration of use was a significant risk factor for cognitive decline, meaning off-label patients with chronic conditions face the longest exposures and greatest cumulative cognitive risk.

Legal Theories for Off-Label Prescribing Claims

Patients who developed cognitive decline or dementia after off-label gabapentin use have multiple legal theories available. Failure-to-warn claims argue that the manufacturer knew or should have known about cognitive risks in off-label populations and failed to update labeling accordingly. Negligent marketing claims target the manufacturer's creation of an off-label market through illegal promotion without conducting the safety studies needed to protect those patients. Fraud-based claims can draw on the 2004 criminal conviction to establish a pattern of prioritizing revenue over safety.

The 2004 guilty plea and $430 million settlement provide powerful evidence that the manufacturer knowingly created the off-label market. Under the learned intermediary doctrine — which normally shields manufacturers by placing prescribing responsibility on physicians — the manufacturer's illegal off-label promotion undermined physicians' independent judgment by corrupting the medical literature and paying opinion leaders to recommend unapproved uses. This corruption of the prescribing chain creates liability that bypasses the traditional learned intermediary defense and reaches the manufacturer directly.

Prescribing Volume and the Scope of Harm

The scale of gabapentin off-label prescribing translates to a massive population at risk for cognitive harm. With over 70 million prescriptions dispensed annually and the majority written for unapproved uses, tens of millions of Americans have been exposed to cognitive risks that were never formally evaluated. Gabapentin ranked as the sixth most prescribed drug in the United States in 2022. Geographic analysis shows highest per-capita prescribing in states with elevated chronic pain prevalence and opioid crisis impact — regions like Appalachia, the rural South, and the Midwest where alternative pain management resources are scarce and patients often have limited access to specialist care that might catch early cognitive decline.

The economic implications are staggering. If even a small percentage of the millions of off-label gabapentin users develop measurable cognitive decline, the aggregate healthcare costs — neurological evaluations, cognitive rehabilitation, premature assisted living placement, lost productivity — run into the billions. This economic reality, combined with the documented criminal history of off-label promotion, positions gabapentin cognitive decline litigation as one of the most significant emerging mass tort actions in pharmaceutical law.

Evidence Preservation for Off-Label Claims

Patients pursuing off-label gabapentin claims should gather evidence demonstrating that their prescription was for an unapproved use. Medical records showing the diagnosis or condition for which gabapentin was prescribed are essential. If the prescribing physician documented the indication as anything other than postherpetic neuralgia or epilepsy, the off-label nature of the prescription is established. Pharmacy records, insurance claim forms with diagnosis codes, and office visit notes all contribute to this documentation. Evidence that the prescribing physician received payments, meals, or speaking fees from Pfizer or gabapentin generic manufacturers — searchable through the CMS Open Payments database — can strengthen claims of manufacturer influence on the prescribing decision.